C. Casetta,P. Santosh,R. Bayley,J. Bisson,S. Byford,C. Dixon,R. J. Drake,R. Elvins,R. Emsley,N. Fung,D. Hayes,O. Howes,A. James,K. James,R. Jones,H. Killaspy,B. Lennox,L. Marchant,P. McGuire,E. Oloyede,M. Rogdaki,R. Upthegrove,J. Walters,A. Egerton,J. H. MacCabe

Abstract:Clozapine is an antipsychotic drug with unique efficacy, and it is the only recommended treatment for treatment-resistant schizophrenia (TRS: failure to respond to at least two different antipsychotics). However, clozapine is also associated with a range of adverse effects which restrict its use, including blood dyscrasias, for which haematological monitoring is required. As treatment resistance is recognised earlier in the illness, the question of whether clozapine should be prescribed in children and young people is increasingly important. However, most research to date has been in older, chronic patients, and evidence regarding the efficacy and safety of clozapine in people under age 25 is lacking. The CLEAR (CLozapine in EARly psychosis) trial will assess whether clozapine is more effective than treatment as usual (TAU), at the level of clinical symptoms, patient rated outcomes, quality of life and cost-effectiveness in people below 25 years of age. Additionally, a nested biomarker study will investigate the mechanisms of action of clozapine compared to TAU.

CLEAR – clozapine in early psychosis: study protocol for a multi-centre, randomised controlled trial of clozapine vs other antipsychotics for young people with treatment resistant schizophrenia in real world settings